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OBJECTIVES The objective of this study was to evaluate the association of high plasma levels of either
C-reactive protein (CRP), lipoprotein (a) (Lp[a]) or total homocysteine (tHCY) with the
long-term prognosis after successful coronary stenting (CS)
BACKGROUND High plasma levels of either CRP, Lp(a) or tHCY may have an impact in coronary artery
disease. However, long-term prospective data after coronary stenting (CS) are limited.
METHODS Four-hundred and eighty-three consecutive patients with either stable or unstable coronary
syndromes were followed for up to three years after successful CS. The composite of cardiac
death, myocardial infarction or rehospitalization for rest unstable angina, whichever occurred
first, was the prespecified primary end point. Moreover, the one-year incidence of clinical
recurrence of symptoms, in-stent restenosis (ISR) and progression of atherosclerosis to a
significant lesion (PTSL) were additionally evaluated. PTSL was defined as an increase by at
least 25% in the luminal diameter stenosis of a known nonsignificant lesion (50% luminal
diameter stenosis) that was located in a nonintervened vessel at restudy, resulting in an
angiographically significant lesion (70% luminal diameter stenosis).
RESULTS By the end of the follow-up, high plasma levels of either CRP or Lp(a) but not tHCY were
independently associated with the primary end point. In particular, CRP 0.68 mg/dl (p 
0.001) or Lp(a) 25 mg/dl (p  0.003) conferred a significantly increased risk. By 1 year, a
CRP 0.68 mg/dl conferred a significantly increased risk for clinical recurrence of symptoms
(p  0.001) or PTSL (p  0.001). None of the studied biochemical markers was related to
ISR.
CONCLUSIONS High plasma levels of either CRP or Lp(a) but not tHCY may be associated with a higher
incidence of late adverse events after successful CS. PTSL in vessels not previously intervened
upon may play a significant role in the underlying pathophysiology as opposed to
ISR. (J Am Coll Cardiol 2002;40:1375–82) © 2002 by the American College of
Cardiology Foundation
Coronary atherosclerosis is a treatable but incurable disease,
and percutaneous coronary intervention (PCI) constitutes
an established therapeutic approach. Although the intro-
duction of stents coupled with new antiplatelet agents has
substantially reduced early and late complications, a signif-
icant proportion of successfully treated patients experience
late nonfatal or fatal ischemic events. The pathophysiologic
mechanisms for these late events include in-stent restenosis
(ISR) or coronary disease progression in other lesions that
had not undergone intervention. The identification of these
high-risk patients is essential in everyday clinical practice
but remains a challenge. To more accurately risk-stratify
these patients with late events, several clinical and angio-
graphic characteristics as well as biochemical markers have
been suggested as possible predictors. In particular, plasma
C-reactive protein (CRP), lipoprotein (a) (Lp[a]) and total
homocysteine (tHCY) have all been proposed as markers for
secondary risk stratification. However, long-term prospec-
tive studies concerning these biochemical markers are lim-
ited or their results are inconsistent (1–8).
METHODS
Study population. The Global Evaluation of New Events
and Restenosis After Stent Implantation (GENERA-
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TION) study was a prospectively designed observational
study to investigate the impact of high plasma levels of
either CRP, Lp(a) or tHCY on the long-term incidence of
clinical events after successful coronary stenting (CS) and to
evaluate globally the contribution of either ISR or progres-
sion of coronary atherosclerosis to these events. For this
purpose, 903 consecutive patients who were admitted from
January 1998 through April 2000 with the diagnosis of
either stable angina, non–ST-segment elevation acute cor-
onary syndrome (NSTACS) or ST-segment elevation acute
myocardial infarction (STEMI) were considered eligible for
the study. Only patients with STEMI who presented within
the first 6 h and NSTACS patients who presented within
24 h of index pain were included. Patients with left
bundle-branch block, infection or inflammatory disease,
malignancy, hepatic dysfunction, plasma creatinine 1.5
mg/dl (upper normal value), a history of myocardial infarc-
tion, coronary revascularization in the last six months or a
left ventricular ejection fraction 35% before current PCI
were excluded.
Of the 903 patients, 501 eligible patients underwent PCI
with stent implantation. Eighteen patients who needed
urgent coronary surgery or experienced in-hospital death or
myocardial infarction were excluded. Thus, 483 patients
with successful CS in 539 vessels (554 lesions) comprised
the study cohort. The Hospital Ethics Committee approved
the study and informed consent was obtained from all
participants.
Data collection. Upon admission, venous blood samples
were obtained before the intravenous administration of
drugs. Coded plasma samples were stored at 24°C for
CRP and Lp(a) analysis, which were performed 24 to 72 h
later. Coded plasma for tHCY measurement was immedi-
ately stored at 80°C and analyzed at the end of the study.
CRP was measured using a quantitative turbidimetric
method (Turbicant, Dade Behring, Germany). Lp(a) was
measured by immunoassay method (N Latex Lp(a), Neph-
elometer BN 100, Dade Behring, Germany). A range of 0.5
to 60 mg/dl and 8 to 160 mg/dl were covered for CRP and
Lp(a), respectively. The upper normal value of CRP is 0.5
mg/dl in the laboratory. Plasma tHCY was measured by an
immunoassay method (FPIA assay, IMx system, Abbott)
with a range of 4 to 500 mol/l. For values below the limit
of detection, the lower limit value was used for statistical
analysis. The results of biochemical markers were not
decoded until the end of the study.
Two independent and experienced angiographers who
had no knowledge of the study performed all quantitative
measurements, using off-line quantitative computerized
analysis. Values were calculated as the mean score given by
the two observers. Intra-observer and inter-observer vari-
ability were 5% and 10%, respectively.
Follow-up and study end points. Before discharge, all
patients were advised for a six-month angiographic restudy.
After discharge, patients were followed up clinically at one,
three and six months and subsequently every six months for
up to three years.
The composite of cardiac death, nonfatal myocardial
infarction or rehospitalization for rest unstable angina
(whichever occurred first) up to three years after discharge
was the prespecified primary end point. The incidence of
clinical recurrence of symptoms (CLR), angiographic ISR
or progression to a significant coronary lesion (PTSL) in
vessels other than the treated ones during the one-year of
follow-up were additionally evaluated. ISR was defined as
50% in-stent stenosis on re-evaluation. In case of ISR in
two stented lesions in the same patient, the more significant
was taken into account. PTSL was defined as an increase by
at least 25% in luminal diameter stenosis of a known
nonsignificant lesion (50% luminal diameter stenosis)
located in a nonintervened vessel at restudy, resulting in an
angiographically significant lesion (70% luminal diameter
stenosis).
Coronary angiography and PCI. Patients with NSTACS
or STEMI were scheduled for coronary angiography and
PCI beyond the third day of admission and after their initial
clinical stabilization or earlier if it was clinically indicated.
Unfractioned heparin (10,000 IU) was given intravenously
at the start of the PCI. Balloon catheters and stents were
selected by the interventionalist. Predilation was performed,
and all stents were deployed at high pressures. The proce-
dure was considered successful if: 1) there were no adverse
events, including death, myocardial infarction or the need
for urgent coronary surgery; 2) the visually estimated resid-
ual stenosis was 30% and 3) there was TIMI 3 flow
distally immediately after stent implantation. Aspirin was
given orally (160 to 325 mg) upon admission to all patients
and was continued indefinitely. Glycoprotein IIb/IIIa in-
hibitors were administered periprocedurally in 21.1% of
patients. All patients received ticlopidine (250 mg b.i.d.) for
four weeks after PCI.
Statistical analysis. Values were expressed as mean  SD
for normally distributed and as median (range) for non-
normally distributed variables. Normal distribution was
Abbreviations and Acronyms
CLR  clinical recurrence of symptoms
CRP  C-reactive protein
CS  coronary stenting
GENERATION  Global Evaluation of New Events
and Restenosis After Stent
Implantation
ISR  in-stent restenosis
Lp(a)  lipoprotein (a)
NSTACS  non–ST-segment elevation acute
coronary syndrome
PCI  percutaneous coronary intervention
PTSL  progression to a significant lesion
ROC  receiver operating characteristics
STEMI  ST-segment elevation myocardial
infarction
tHCY  total homocysteine
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evaluated with Kolmogorov–Smirnov test. Values were
compared using t test or Mann-Whitney U test as appro-
priate. Associations between categorical variables were
tested by Fisher’s test. Receiver operating characteristics
(ROC) curves were constructed for biochemical markers to
evaluate their accuracy in the prediction of the primary end
point (measured by the area under the ROC curve, range
0.5 to 1). To avoid arbitrary cutoff points of biochemical
markers for the prediction of the primary end point, the
optimal cutoff points with the highest predictive accuracy,
which separated the cohort into two populations, were
estimated by ROC analysis. If a biochemical marker didn’t
accurately predict the primary end point, its median value
was selected as the cutoff point. Event-free survival was
analyzed with Kaplan–Maier method and log-rank used for
comparisons between curves. Univariate and multivariate
Cox proportional hazards regression analyses were con-
structed for the determination of univariate and multivariate
predictors of the composite primary end point or of or its
components. Univariate and multivariate binary logistic
regression analysis was constructed to evaluate the univariate
or multivariate predictors of ISR or PTSL. All variables,
presented in Tables 1 and 2, were evaluated as possible
predictors of the study end points and those with a p  0.1
were included into the multivariate models. All tests were
two-tailed, and a p  0.05 was considered as significant.
Statistical analysis was performed with SPSS statistical
software (release 10.0, SPSS, Chicago, Illinois).
RESULTS
Baseline characteristics. Baseline clinical characteristics
are shown into Tables 1 and 2. The majority of the included
STEMI patients had received intravenous thrombolysis
(147/177; 83%) after admission and five underwent either
primary or rescue PCI. Twenty-five of the included STEMI
patients (with a pre-PCI left ventricular ejection fraction
35%) had not received acute reperfusion therapy because
of contraindications.
Significant univariate associations between biochemical
markers and other baseline variables. Stable angina pa-
tients had significantly lower baseline CRP values than
those with either NSTACS (median, range 0.52, 0.50 to
1.20 mg/dl vs. 0.59, 0.50 to 4.10 mg/dl; p  0.001), or
STEMI (median, range 0.59, 0.50 to 5.10 mg/dl; p 
0.001). There was no significant difference in plasma levels
of either Lp(a) or tHCY among the groups defined by the
qualified coronary syndrome (data not presented). The
median baseline tHCY level was 8 mol/l higher in patients
with a history of coronary bypass grafting than in patients
without (21 mol/l vs. 13 mol/l; p  0.01); 5 mol/l
higher in patients with a history of cerebrovascular or
peripheral artery disease than the patients without such a
history (18 mol/l vs. 13 mol/l, p  0.001); 4 mol/l
higher in patients75 years of age (17 mol/l vs. 13 mol/l
in patients 75 years; p  0.01). Moreover, median
baseline tHCY was 2 mol/l higher in patients with
multivessel coronary artery disease than those with single
artery disease (14 mol/l vs. 12 mol/l; p  0.001) and 1
mol/l higher in diabetics than nondiabetics (14 mol/l vs.
13 mol/l; p 0.08). No other significant associations were
found between the studied biochemical markers and the
other baseline variables. Furthermore, biochemical markers
were not significantly interrelated (data not presented).
Long-term follow-up. Clinical follow-up was obtained in
465 (465/483; 96.3%) patients at 22.1  8.3 months (1 to
37 months). By the end of follow-up, 20 patients (20/465;
4.3%) died, 21 (21/465; 4.5%) suffered from a nonfatal
myocardial infarction and 35 (35/465; 7.5%) were rehospi-
Table 1. Baseline Clinical Characteristics
Age (yrs) 59.3  10
Male 396 (82)
Hypertension 208 (43.1)
Cigarette smoker 321 (66.5)
Diabetes 95 (19.7)
Hypercholesterolemia 262 (54.2)
History of MI* 42 (8.7)
History of PCI* 20 (4.1)
History of CABG* 12 (2.5)
History of CVD or PVD 38 (7.9)
CRP median (range) mg/dl 0.58 (0.50–5.10)
Lp(a) median (range) mg/dl 19 (8–103)
tHCY median (range) mol/l 13 (4–50)
Qualifying event
Stable angina 107 (22.15)
NSTACS 199 (41.20)
STEMI 177 (36.65)
*History occurrence 6 months before study or greater. Values are mean SD or n (%)
or as given.
CABG  coronary artery bypass grafting; CRP  C-reactive protein; CVD 
cerebrovascular disease; Lp(a)  lipoprotein (a); MI  myocardial infarction;
NSTACS  non–ST-segment elevation acute coronary syndrome; PCI  percuta-
neous coronary intervention; PVD  peripheral vascular disease; STEMI  ST-
segment elevation myocardial infarction; tHCY  total homocysteine.
Table 2. Angiographic- and PCI-Related Data
Multivessel disease 179 (37.1)
LVEF (%) 52.1  6.8
From admission through PCI in days 6.3  3.1
Target vessel (n  539) (%)
Left anterior descending artery 279/539 (51.8)
Right coronary artery 158/539 (29.3)
Left circumflex artery 96/539 (17.8)
Graft 6/539 (1.1)
B2 or C target lesion 318/554 (57.4)
Number of stents per lesion 1.1  0.4
Stent length (mm) 15.4  8.1
Preprocedural target lesion characteristics
Lesion stenosis (%) 82.9  8.1
RLD (mm) 3.30  0.38
MLD (mm) 0.56  0.28
Postprocedural target lesion characteristics
In-stent residual stenosis (%) 8.6  8.5
RLD (mm) 3.41  0.39
MLD (mm) 3.10  0.44
Acute gain (mm) 2.55  0.47
Values are mean  SD or n (%) or as given.
LVEF  left ventricular ejection fraction; MLD  minimal lumen diameter;
PCI  percutaneous coronary intervention; RLD  reference lumen diameter.
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talized because of rest unstable angina for a total of 76
primary events. By one year, 121 patients (121/465 26%)
developed CLR, including 10 (10/465; 2.1%) who died, 15
(15/465 3.2%) with a nonfatal myocardial infarction, 25
(25/465; 5.4%) who rehospitalized because of rest unstable
angina, 68 (68/465; 14.6%) who developed new exertional
angina and 3 (3/465; 0.6%) with exacerbated heart failure.
During this one-year time period, 309 (309/465; 66.5%)
patients underwent angiographic restudy, including 114
(114/121; 94.2%) with CLR and 195 (195/344; 57%)
asymptomatic. There were no significant differences con-
cerning the plasma levels of the study biochemical markers
between asymptomatic patients with or without angio-
graphic restudy (data not presented). ISR was observed in
108 (108/309; 34.9%) patients, including 69 (69/74 93.2%)
with new exertional angina or heart failure, 7 (7/15; 46.6%)
with nonfatal myocardial infarction, 14 (14/25; 56%) who
rehospitalized because of rest unstable angina, and 18
(18/195; 9.2%) without symptoms. PTSL was observed in
47 (47/309; 15.2%) patients, including 13 (13/74; 17.6%)
with new exertional angina or exacerbated heart failure, 9
(9/15; 60%) with new nonfatal myocardial infarction, 14
(14/25; 56%) with rest unstable angina and 11 (11/195;
5.6%) asymptomatic.
Biochemical markers and primary end point. Receiver
operating characteristics analysis indicated that either CRP
or Lp(a) but not tHCY had reasonable accuracy for the
composite primary end point (Fig. 1A). The optimal cutoff
points of CRP and Lp(a) were 0.68 mg/dl and 25 mg/dl,
respectively (Figs. 1B and 1C). Patients with CRP values
0.68 mg/dl were at higher risk for the composite end
point or its components than patients with CRP values
0.68 mg/dl for up to three years (Table 3, Figs. 2A and
3A). In particular, the former were at higher risk for either
rehospitalization for rest unstable angina (hazards ratio
[HR] 7.10; 95% CI 3.30 to 15.26; p  0.001), nonfatal
myocardial infarction (HR 5.67; 95% CI 2.19 to 14.66; p 
0.001) or cardiac death (HR 3.16; 95% CI 1.25 to 7.98; p
0.01) than the latter. Moreover, patients with Lp(a) values
25 mg/dl were at higher risk for either the composite
primary end point, rehospitalization for rest unstable angina
(HR 2.09; 95% CI 1.16 to 4.12; p  0.03) or nonfatal
myocardial infarction (HR 3.31; 95% CI 1.33 to 8.22; p 
0.01) than those with Lp(a)25 mg/dl but not for cardiac
death (HR 1.27; 95% CI 0.48 to 3.34; p  0.87) (Table 3,
Figs. 2B and 3B). There was no significant difference in the
incidence of the end points between the groups of tHCY
(Table 3, Figs. 2C and 3C).
Figure 1. ROC curves of biochemical markers for the primary end point (A) and cutoff points for CRP (B) or Lp(a) (C). ROC area was 0.77; 95% CI
0.70 to 0.83; p  0.001, ROC area 0.67; 95% CI 0.60 to 0.72; p  0.001, ROC area 0.51; 95% CI 0.44 to 0.59; p  0.71 for CRP, Lp(a) and tHCY,
respectively. CRP  C-reactive protein; Lp(a)  lipoprotein(a); Se  sensitivity; Sp  specificity; tHCY  total homocysteine.
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Biochemical markers and CLR, ISR or PTSL during the
first year. The distribution of CLR among the groups is
presented in Figure 4 (Figs. 4A to 4C). By univariate Cox
proportional hazards analysis, several variables, including a
plasma CRP 0.68 mg/dl (p  0.001) or Lp(a) 25 mg/dl
(p  0.05), were related to the one-year CLR. However, by
multivariate Cox proportional hazards analysis, only diabe-
tes mellitus (HR 1.88; 95% CI 1.27 to 2.78; p  0.002),
post-PCI in-stent residual stenosis (HR 1.08; 95% CI 1.05
to 1.10; p 0.001), B2- or C-treated lesion (HR 1.72; 95%
CI 1.15 to 2.57; p  0.008), a plasma CRP  0.68 mg/dl
(HR 2.70; 95% CI 1.64 to 3.81; p  0.001) and left
ventricular ejection fraction (HR 0.97; 95% CI 0.95 to 0.99;
p  0.04) were independent predictors of the one-year
CLR. None of the study biochemical marker was related to
ISR (Figs. 4A to 4C). The distribution of PTSL between
the groups is depicted in Figures 4A to 4C. By univariate
logistic regression analysis, several variables, including a
plasma CRP 0.68 mg/dl (p 0.001) or Lp(a)25 mg/dl
(p  0.05), were positively related to PTSL. However, by
multivariate logistic analysis, only a plasma CRP 0.68
mg/dl (relative risk 19.34; 95% CI 8.80 to 62.97; p 0.001)
conferred a significant increased risk.
DISCUSSION
CRP. C-reactive protein is a sensitive and nonspecific
inflammatory marker (9). In this study increased CRP levels
conferred a significant increased risk for new fatal or
nonfatal cardiac events up to three years after successful CS.
This association was significant by univariate and multivar-
iate analysis and after adjustment for the qualifying event.
Table 3. Predictors of the Composite Primary End Point
Univariate Cox Proportional
Hazards Regression
Multivariate Cox Proportional
Hazards Regression
HR (95% CI) p Value HR (95% CI) p Value
Stable angina 0.28 (0.12–0.64) 0.003 0.81 (0.28–2.17) 0.58
NSTACS 1.94 (1.23–3.06) 0.003 1.77 (1.10–2.92) 0.03
History of CVD or PVD 2.21 (1.17–4.18) 0.02 1.95 (1.14–3.28) 0.03
Diabetes 2.45 (1.53–3.92)  0.001 2.12 (1.30–3.45) 0.002
LVEF (%) 0.94 (0.92–0.98) 0.001 0.96 (0.92–0.98) 0.01
Type B2 or C lesion 1.79 (1.14–2.80) 0.01 1.51 (0.86–2.44) 0.25
Postprocedural MLD (mm) 0.32 (0.18–0.58)  0.001 0.84 (0.41–1.60) 0.67
Acute gain (mm) 0.43 (0.26–0.72) 0.001 1.00 (0.51–2.44) 0.76
In-stent residual stenosis (%) 1.06 (1.04–1.09)  0.001 1.05 (1.02–1.08) 0.001
CRP  0.68 mg/dl 5.13 (3.15–8.38)  0.001 5.07 (3.08–8.35)  0.001
Lp(a)  25 mg/dl 1.99 (1.28–3.14) 0.002 2.42 (1.52–3.84) 0.003
CI  confidence interval; CVD  cerebrovascular disease; CRP  C-reactive protein; HR  hazard ratio; Lp(a)  lipoprotein
(a); LVEF left ventricular ejection fraction; MLD minimal lumen diameter; NSTACS non–ST-segment elevation acute
coronary syndrome; PVD  peripheral vascular disease.
Figure 2. Distribution of the three-year composite primary end point or its components between the subgroups of the studied biochemical markers. CD 
cardiac death; CPE  composite primary end point; CRP  C-reactive protein; Lp(a)  lipoprotein(a); MI  nonfatal myocardial infarction; tHCY 
total homocysteine; UA  rehospitalization for rest unstable angina. *p  after adjustment for the other univariate predictors of the event.
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These results are in agreement with previous prospective
studies, which have consistently showed that elevated
plasma CRP levels are associated with the incidence of
short- or long-term ischemic complications after PCI with
or without stent implantation (1,10–12). Moreover, in this
study, a strong and independent significant association was
also found between elevated CRP and progression of
atherosclerosis (in not previously treated vessels) during the
first year of follow-up. This is consistent with the findings
of a previous retrospective study from our group in a
different cohort of patients. Thus, a low-grade inflam-
matory process associated with an elevated plasma CRP
may predispose to atherosclerotic plaque progression and
the induction of future fatal or nonfatal ischemic com-
plications.
However, elevated plasma CRP levels were not related to
the rate of ISR. This finding is in disagreement with the
results reported by Walter et al. (11). These investigators
studied a cohort of 256 patients in whom 86% had a
6-month angiographic follow-up and observed that tertiles
of CRP upon admission were significantly associated with
ISR. In our study, 114 symptomatic (114/121; 94%) and
195 (195/344; 56.7%) asymptomatic patients underwent
restudy during the first year, corresponding to a 67%
angiographic follow-up. The lower rate of recatheterization
in the present study, as well as differences in either the
structure of the studied populations or the statistical approach
used, may account for these disparate findings. However, in
GENERATION, 34% (26/76) of primary acute coronary
events occurred after the first year, when ISR was less likely to
occur. This also suggests that progression of atherosclerosis in
untreated coronary plaques rather than ISR may be a respon-
Figure 3. Kaplan-Meier curves of the composite primary end point between the groups of CRP (A), Lp(a) (B), and tHCY (C) defined by the cutoff points
of these biochemical markers. CRP  C-reactive protein; Lp(a)  lipoprotein(a); tHCY  total homocysteine.
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sible mechanism for the high CRP-related excess in clinical
events. More studies are needed to elucidate this issue.
Lp(a). Lipoprotein (a) has been considered as a link be-
tween atherosclerosis and thrombosis because of its similar-
ity to both low density lipoprotein and plasminogen (13).
Two larger previous angiographic studies could not show a
significant relationship between high plasma Lp(a) levels
and the 6-month ISR rate (5,6) or one-year clinical outcome
(5). In concordance with these reports, we found no
relationship between Lp(a) and one-year CLR or ISR.
However, Lp(a) conferred a significantly increased risk of
the primary end point at the end of the follow-up (Fig. 2B).
An elevated plasma Lp(a) level conferred only a marginally
significant increased risk of PTSL, and this association was
not as strong as between CRP and PTSL. It is possible that
a more protracted latent period may be needed in order to
manifest clinically the unfavorable influence of an elevated
Lp(a) on atherosclerotic plaque instability.
tHCY. Although elevated plasma tHCY levels have been
considered as an independent risk factor of coronary artery
disease, the role of hyperhomocystinemia in the prediction
of restenosis and clinical long-term prognosis after PCI is
unclear (6–8). No significant association between plasma
tHCY and any end point was found in this study.
Small previous studies have found a positive relationship
between elevated plasma tHCY levels and angiographic
restenosis after PCI with (8) or without (7) stent implan-
tation. However, because of the small sample size in these
studies, confounding variables (14,15) may not have been
controlled. In GENERATION, a strong association be-
tween tHCY levels and cardiovascular risk profile was
found, which is consistent with previous epidemiological
studies (15).
Study limitations. The determined cutoff points of either
CRP or Lp(a) must not be considered as generally applied.
These cutoff points optimally dichotomize the GENERA-
TION population for the prediction of the study end points.
Moreover, the recently recommended high-sensitivity CRP
assay was not available at the beginning of the study and
there is not a standardized analytic method for Lp(a) levels
determination.
In addition, our findings concerning ISR or PTSL may
have been modified if more asymptomatic patients under-
went an angiographic restudy.
Conclusions. The results of the GENERATION study
indicate that high plasma levels of either CRP or Lp(a) but
not tHCY confer an increased risk for the long-term cardiac
mortality and morbidity after successful CS. Although the
role of ISR in this increased risk could not be definitely
excluded, a significant progression of atherosclerosis in not
previously intervened atherosclerotic plaques appears to be
involved.
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